Search results
Results from the WOW.Com Content Network
DePuy identified reasons for the failure of the hip replacement system as component loosening, component malalignment, infection, fracture of the bone, dislocation, metal sensitivity and pain. Additional complications from the hip replacement system may include increased metal ion levels in the blood, bone staining, necrosis, swelling, nerve ...
On August 24, 2010, DePuy, a subsidiary of American giant Johnson & Johnson, recalled its ASR (articular surface replacement) hip prostheses from the market. DePuy said the recall was due to unpublished National Joint Registry data showing a 12% revision rate for resurfacing at five years and an ASR XL revision rate of 13%.
DePuy Synthes (/ dəˈpjuː /) is a franchise of orthopaedic and neurosurgery companies. Acquired by Johnson & Johnson in 1998, its companies form part of the Johnson & Johnson Medical Devices group. DePuy develops and markets products under the Codman, DePuy Mitek, DePuy Orthopaedics and DePuy Spine brands.
Metallosis. Metallosis is the medical condition involving deposition and build-up of metal debris in the soft tissues of the body. [1] Metallosis has been known to occur when metallic components in medical implants, specifically joint replacements, abrade against one another. [1] Metallosis has also been observed in some patients either ...
New diabetes and weight-loss drugs may benefit patients undergoing hip replacement, without adding to complication risks, according to preliminary data released on Monday at a large meeting of ...
D019644. MedlinePlus. 002975. [edit on Wikidata] Hip replacement is a surgical procedure in which the hip joint is replaced by a prosthetic implant, that is, a hip prosthesis. [1] Hip replacement surgery can be performed as a total replacement or a hemi/semi (half) replacement.
A multistate team of litigators helped to negotiate a settlement with medical technology firm Stryker Corp. on Friday. Stryker, a Fortune 500 company, had been faced with multidistrict as well as ...
The following are settlements reached with US authorities against pharmaceutical companies to resolve allegations of "off-label" promotion of drugs. Under the Federal Food, Drug, and Cosmetic Act, it is illegal for pharmaceutical companies to promote their products for uses not approved by the Food and Drug Administration (FDA), and corporations that market drugs for off-label indications may ...